Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples